IDT launches oPools Oligo Pools

19 Aug 2019

The longest, highest fidelity, and ready-to-use custom oligo pools on the market.

Integrated DNA Technologies (IDT) has launched oPools Oligo Pools – ready-to-use pools of high-quality DNA oligos up to 350 nucleotides long. Thanks to its industry-leading proprietary manufacturing processes and 30 years of dedication to exceptional quality products, IDT is able to provide oligo pools unparalleled in uniformity at yields that accelerate experiments by eliminating time-consuming and bias-producing PCR amplification steps required by other commercially available pools.

IDT launches oPools Oligo Pools

Pooled oligos are widely used in high-throughput workflows in synthetic biology, diagnostic development, and drug discovery. For optimum performance, such pools must be uniformly comprised of full-length oligos of the highest possible fidelity (oligos of correct sequence and length). IDT’s proprietary manufacturing platform produces long oligos more accurately, rapidly, and reliably than any other DNA synthesis platform, enabling timely delivery of the highest fidelity and most uniform oligonucleotide pools available.

oPools' low error rate of less than 1 in 2000 nucleotides, coupled with high per oligo yields, allow researchers to proceed immediately and confidently into their downstream workflows for projects including CRISPR library construction, protein screening, and gene assembly. For synthetic biologists, quick access to affordable, high-quality oligo pools that can go directly into their pipeline without the hands-on time required for PCR amplification allows for faster and more impactful “Design, Build, Test” cycles so critical to discovery.

Early adopters of the product offering have benefitted from the high-quality oPools for their applications, including ArcherDX, a molecular technology company dedicated to developing breakthrough solutions that advance personalized genomic medicine. Josh Stahl, Chief Scientific Officer of ArcherDX, commented: “ArcherDX evaluated several comparable product offerings from array-based providers, and the oPools from IDT were the best solution available to deliver the performance, speed, and ease-of-use necessary to meet our exacting requirements.”

Unlike suppliers that opt for array or silicon chip-based batch synthesis, IDT employs a unique, solid-support manufacturing platform that individually synthesizes every oligo. This delivers the highest percentage of full-length DNA in the industry. IDT’s manufacturing approach also ensures that each species of oligo is represented and at greater uniformity in the resulting pool allowing for a more complete experiment downstream. For IDT, 95% of sequences in oPools Oligo Pools are represented within 1.5x of the mean, compared to 90% within 4x of the mean for a comparative supplier.

Trey Martin, President of IDT, commented: “IDT has historically avoided the traditional pools market due to our capacity being fully booked. Two years into our 6th-generation synthesis platform, we have alleviated all capacity concerns and are thrilled to offer our unique take on oligo pools. They leverage the ultra-high fidelity of IDT synthesis to give heretofore unobtainable experimental results from the traditional microarray-driven approach. We have been in beta testing for 6 months and customers are delighted with the results. Our pool deliveries are in picomoles, eliminating the need to do any pre-amplification or other pre-work before the pool can be used. With lengths up to 350 bases and error rates below one per 2kB, these are the same oligos that IDT relies on for our own high-throughput gene assembly processes.”

IDT’s oPools are ready-to-run, affordable pools of customized single-stranded DNA sequences between 40-350 nt in length. There is no minimum order, pools are compatible with downstream cloning methods, and have a short turnaround time of just four to seven business days from ordering to delivery. oPools™ unparalleled concentration, uniformity, and low error rates assure high target specificity and provide researchers with the utmost confidence in results.

Read More

Related news

Novartis receives EC Approval for next-gen anti-VEGF treatment for wet AMD

Novartis receives EC Approval for next-gen anti-VEGF treatment for wet AMD

21 Feb 2020

Beovu is the only anti-VEGF treatment approved in Europe for wet AMD that offers the option to start eligible patients on 3-month dosing intervals immediately after the loading phase.

Read more 
Catalent to manufacture first-in-class mAb targeting solid tumours

Catalent to manufacture first-in-class mAb targeting solid tumours

11 Feb 2020

ZM008 could have potential benefits for the treatment of prostate cancer.

Read more 
BD completes clinical trial for its wearable injector

BD completes clinical trial for its wearable injector

11 Feb 2020

The pre-filled, pre-assembled injector is designed to prioritize safety, convenience and usability while delivering high-value drug treatments in the comfort of an in-home environment.

Read more 
New Velesco Pharma clinical manufacturing facility begins operations

New Velesco Pharma clinical manufacturing facility begins operations

5 Feb 2020

The facility will triple the company’s cGMP clinical trial manufacturing capacity.

Read more 
Inovio and Beijing Advaccine to advance vaccine against Coronavirus

Inovio and Beijing Advaccine to advance vaccine against Coronavirus

30 Jan 2020

Agreement will facilitate clinical trial translations in China.

Read more 
First human trial of monoclonal antibody to prevent malaria opens

First human trial of monoclonal antibody to prevent malaria opens

28 Jan 2020

If proven safe and effective, mAb CIS43LS might be used prophylactically by tourists, medical workers or military personnel who travel to areas where malaria is common.

Read more 
Thermo launches next-generation, compressor-free plate sealer

Thermo launches next-generation, compressor-free plate sealer

28 Jan 2020

Features new functionalities and capabilities making it versatile for a variety of both manual and automated microplate processing life science applications.

Read more 
Merck invests in biotech development facility in Switzerland

Merck invests in biotech development facility in Switzerland

27 Jan 2020

€250 million to be invested during the 2019-2022 period in new facility bridging research and manufacturing.

Read more 
Grey Wolf Therapeutics secures funding for cancer therapies development

Grey Wolf Therapeutics secures funding for cancer therapies development

21 Jan 2020

The company targets ERAP antigen presentation pathways with the aim of ‘illuminating’ non-responsive tumours for attack and destruction by the immune system.

Read more 
Diabetes diagnosis - now a matter of sweat and tears?

Diabetes diagnosis - now a matter of sweat and tears?

21 Jan 2020

No need to draw blood; researchers develop smart technology to diagnose diabetes and treat diabetic retinopathy.

Read more